New research shows posture-driven retinal vascular changes can predict diabetic retinopathy progression, with smartphone-based imaging detecting early microvascular dysfunction. A five-year study found abnormal arteriolar tortuosity during postural shifts increased progression risk over two-fold.
Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.
MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.
A UK trial found continuous glucose monitoring improved HbA1c and time in range for adults with type 2 diabetes using basal insulin. Dexcom is also awaiting a Medicare decision on broader CGM coverage for non-insulin users.
AbbVie shares declined 2% on March 13, 2026, amid reduced trading volume, while BMO Capital maintained its Outperform rating following Phase 1 obesity drug trial data for ABBV-295.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07553325 |
Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes |
NOT_YET_RECRUITING | NA |
| NCT07548372 |
SPARK-CGM Implementation |
NOT_YET_RECRUITING | NA |
| NCT07477067 |
Exercise and Protein Efficiency in T2D |
RECRUITING | NA |
| NCT07463209 |
Integrating New Skills Into Diabetes Education With CGM |
NOT_YET_RECRUITING | NA |
| NCT07422831 |
T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking |
ENROLLING_BY_INVITATION | NA |
| NCT07394075 |
Clinical Decision Support With Continuous Glucose Monitoring Data for Managing Type 2 Diabetes |
ENROLLING_BY_INVITATION | |
| NCT07225218 |
New T-UP: Engaging Vulnerable Students in Diabetes Prevention |
RECRUITING | NA |
| NCT07201532 |
Disease Modification Outcomes in Diabetes: a Delphi Study |
NOT_YET_RECRUITING | |
| NCT07181304 |
Peer Support and Remote Patient Monitoring for Black Adults With Type 2 Diabetes |
NOT_YET_RECRUITING | NA |
| NCT07173543 |
IH, Brain Health, and T2D |
RECRUITING | NA |
